CAPTRUST Financial Advisors
BCRX icon

CAPTRUST Financial Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352K Buy
35,218
+19,331
+122% +$175K ﹤0.01% 2452
2026
Q1 		$151K Sell
15,887
-1,853
-10% -$14.4K ﹤0.01% 2741
2025
Q4 		$138K Sell
17,740
-1,839
-9% -$13.3K ﹤0.01% 2577
2025
Q3 		$149K Sell
19,579
-2,526
-11% -$21K ﹤0.01% 2469
2025
Q2 		$198K Buy
22,105
+1,527
+7% +$14.2K ﹤0.01% 2309
2025
Q1 		$154K Buy
20,578
+4,080
+25% +$32.9K ﹤0.01% 2198
2024
Q4 		$124K Buy
16,498
+224
+1% +$1.7K ﹤0.01% 2188
2024
Q3 		$124K Buy
16,274
+2,644
+19% +$20.1K ﹤0.01% 2190
2024
Q2 		$84.2K Buy
13,630
+345
+3% +$1.9K ﹤0.01% 2120
2024
Q1 		$67.5K Buy
+13,285
New +$74.7K ﹤0.01% 2073
2022
Q3 		– Sell
-6,421
Closed -$68K – 2262
2022
Q2 		$68K Sell
6,421
-166
-3% -$1.71K ﹤0.01% 2507
2022
Q1 		$107K Buy
6,587
+341
+5% +$5.47K ﹤0.01% 2211
2021
Q4 		$87K Sell
6,246
-1,571
-20% -$20.8K ﹤0.01% 2261
2021
Q3 		$112K Buy
7,817
+2,624
+51% +$41.4K ﹤0.01% 1982
2021
Q2 		$82K Hold
5,193
– – ﹤0.01% 2174
2021
Q1 		$53K Sell
5,193
-657
-11% -$6.77K ﹤0.01% 2394
2020
Q4 		$44K Sell
5,850
-1,250
-18% -$6.44K ﹤0.01% 1885
2020
Q3 		$25K Buy
7,100
+3,628
+104% +$15.5K ﹤0.01% 1875
2020
Q2 		$17K Buy
+3,472
New +$13.9K ﹤0.01% 2002

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

CAPTRUST Financial Advisors's BCRX Position: Q2 2026 in Review

CAPTRUST Financial Advisors increased its BioCryst Pharmaceuticals (BCRX) stake by 122% in Q2 2026, buying an estimated $175K and bringing the position to 35,218 shares worth $352K. The position accounts for ﹤0.01% of the portfolio, ranked #2452.

CAPTRUST Financial Advisors first reported a position in BCRX in Q2 2020 and has held it in 19 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • CAPTRUST Financial Advisors held 35,218 shares of BioCryst Pharmaceuticals worth $352K as of Q2 2026.
  • CAPTRUST Financial Advisors bought 19,331 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $175K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #2452 holding.
  • CAPTRUST Financial Advisors first reported a position in BioCryst Pharmaceuticals in Q2 2020 and has held it in 19 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.